Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Cancer
Interventions: GSK2118436, Midazolam; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Nashville, Tennessee + 1 more

Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Interventions: CGT9486, Sunitinib, Midazolam; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more

Conditions: Agitation,Psychomotor
Interventions: Haloperidol Injection, Ziprasidone Injection, OLANZapine Injection, Midazolam injection; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 737 participants
Timeline: 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: alprazolam, Placebo, PF-00572778; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions: Dexmedetomidine, Lorazepam 2 MG/ML; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anesthesia, Psychomotor Status
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Midazolam, Oral Placebo, Intranasal Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 12
States / cities: Birmingham, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more

Conditions: Colonoscopy
Interventions: Remimazolam, Midazolam, Placebo; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more

Conditions: Abuse Liability of Staccato Alprazolam
Interventions: Inhaled placebo + oral placebo, Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, Oral alprazolam 1 mg, Oral alprazolam 2 mg, Oral alprazolam 4 m, Oral alprazolam 2 mg qualifying session, Oral placebo qualifying session; Drug
Lead sponsor: Nova Pneuma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcohol Withdrawal Syndrome
Interventions: Diazepam; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anesthesia
Interventions: Dexmedetomidine and Midazolam, Propofol, Midazolam, and Fentanyl; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obesity, Morbid, Surgery, Bariatric Surgery Candidate
Interventions: Neurontin, Dilaudid Injectable Product, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Zofran Injection, Scopolamine patch, Ativan, Flexeril Oral Product, Tylenol Suspension; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Alcohol Withdrawal Syndrome
Interventions: Gabapentin, Benzodiazepines, Divalproex Sodium; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Schizophrenia, Alzheimer's Disease, Dementia
Interventions: Aripiprazole, Olanzapine, Risperidone; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Colonoscopy, Endoscopy, Digestive System, Conscious Sedation
Interventions: Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System), benzodiazepines and opioid sedation; Device · Other
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Fayetteville, North Carolina • Winston-Salem, North Carolina + 4 more

Conditions: Complex Regional Pain Syndromes
Interventions: Ketamine, Midazolam, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2099
U.S. locations: 1
States / cities: Stanford, California

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Escondido, California • Garden Grove, California • National City, California + 4 more

Conditions: Healthy Volunteer
Interventions: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Pain
Interventions: Lidocaine, Lidocaine and midazolam (PREMIX), Midazolam; Drug
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 7 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar I Disorder
Interventions: Injectable Risperidone (Consta) or oral antipsychotic; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more

Conditions: Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
Interventions: risperidone, olanzapine, aripiprazole; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 18 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depression, Bipolar
Interventions: Olanzapine, Fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Schizophrenia
Interventions: perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 54
States / cities: Chula Vista, California • Los Angeles, California • Orange, California + 45 more

Conditions: Healthy
Interventions: LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Search by objective public record fields.

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Driving Skills Recovery Following Procedural Sedation for Gastrointestinal Endoscopy

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

Staccato Alprazolam Abuse Liability

Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome

A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation

Multimodal Analgesia Effect on Post Surgical Patient

Gabapentin for Alcohol Withdrawal Syndrome

Side Effects of Newer Antipsychotics in Older Adults

Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

PREMIX vs PREMED Intranasal Lidocaine and Midazolam

Risperdal Consta for Bipolar Disorder

Metabolic Effects of Antipsychotics in Children

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

CATIE- Schizophrenia Trial

A Study of LY3484356 in Healthy Female Participants